XOMA’s merger with Ligand moved into a more mechanical phase on Monday, July 13, 2026. Nasdaq said XOMA stockholders approved the transaction, set July 13 as the anticipated last trading day for XOMA, and said the stock would be halted after the after-hours session at around 7:50 p.m. ET. Nasdaq also said the merger was tentatively scheduled to close before the market open on July 14, with suspension effective July 15 if the closing happened as planned.
That would already matter for options traders in a plain cash merger. What makes this phase more interesting is that XOMA common holders are also slated to receive one non-transferable contingent value right, or CVR, per share, tied to the Janssen litigation, while XOMA’s preferred issues are moving toward mandatory redemption. That means the practical options lesson is no longer just “cash deal equals capped upside.” It is about final-session execution, residual time value, assignment discipline, and waiting for the exact OCC contract-adjustment mechanics instead of guessing them.
This article is for market commentary and options education only. It is not financial advice, investment advice, trading advice, or a recommendation to buy or sell any security or options contract. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure.
What changed on July 13
Nasdaq’s July 13 corporate-actions alert tightened the event path in several ways at once:
| Item | Newly stated timing or term |
|---|---|
| Stockholder approval | Approved on July 13, 2026 |
Anticipated last trading day for XOMA |
July 13, 2026 |
| Anticipated halt timing | After the after-hours session at around 7:50 p.m. ET on July 13 |
| Tentative closing path | Before the market open on July 14, 2026 |
| Marketplace suspension | Effective July 15, 2026, if the merger closes |
| Common-stock consideration | USD 39.00 in cash per share |
| Additional common-stock consideration | One non-transferable CVR per share, payable July 14 |
| Preferred treatment | XOMAO and XOMAP move toward mandatory redemption at USD 25.00 per share, plus applicable accrued dividends under their terms |
That is a real phase change from the April announcement. At the announcement stage, traders were mostly comparing the cash consideration with the stock price and asking how much spread risk remained. At the July 13 stage, the more useful questions become procedural: when normal stock trading ends, whether listed options still carry meaningful residual extrinsic value, how assignment risk behaves into a halt, and whether the eventual OCC memo treats the CVR and cash package exactly the way traders assume.
Why This Matters For Options Traders
1. This is not a plain one-number merger problem
If XOMA holders were only receiving a simple all-cash payment, many traders would reduce the setup to a capped-upside instrument with shrinking time value. The CVR complicates that shortcut. The CVR is tied to litigation proceeds, is non-transferable, and is not expected to trade on an exchange. That does not automatically tell you how OCC will treat listed options after the close, and it does not justify making up contract terms before the official memo arrives.
That is the first important discipline point. A stockholder package and an option deliverable are related, but they are not identical until OCC says how the contract will be adjusted. Traders who forget that can overstate or understate what the listed chain is really worth in the final hours.
2. Final-session management matters more than the XOMA business story
By the time a stock has an anticipated last trading day and after-hours halt, it is no longer primarily trading as an open-ended view on the issuer’s stand-alone future. It is trading as an event-driven instrument with a shrinking clock. That changes how options traders should think about the name.
The market focus shifts away from royalty-portfolio growth, litigation optionality in the abstract, or whether Ligand paid a fair strategic price. The more immediate concern becomes whether the remaining option premium is mostly intrinsic value, whether any residual extrinsic value is likely to compress further, and whether assignment risk is still live into the halt window.
If you need the mechanics behind that distinction, the clean refreshers are how options pricing works: intrinsic value vs time value, options expiration, assignment, and exercise explained, and early assignment risk in options trading: when and why it happens.
3. The CVR creates uncertainty, not a free extra payout for options
The easiest mistake in this setup is to treat the CVR as if it were a clean, instantly monetizable add-on with no ambiguity. It is not. The CVR depends on future litigation proceeds, carries high contingency, and is separate from the immediate cash consideration. That means the stockholder economics have an extra piece, but that piece is not the same as cash in hand at the close.
For options traders, the practical lesson is simple: do not assume the chain should price the CVR like ordinary cash value. The more contingent and non-transferable the extra consideration is, the more important it becomes to wait for the contract-adjustment language instead of treating back-of-the-envelope deal math as settled fact.
4. Capital-structure side effects matter, but only in the right way
Nasdaq’s alert also points to mandatory redemptions for XOMAO and XOMAP. That matters because it confirms the whole capital structure is being pushed through an end-state reorganization, not just the common stock. But common-stock options traders should be careful not to overread that detail.
Preferred redemptions help show that the deal mechanics are broad and near-term. They do not, by themselves, tell you the final listed-options deliverable on XOMA. They are context, not a substitute for OCC’s actual memo.
5. Liquidity can become less intuitive even if the headline terms look simple
Final-session merger names often look easier than they are. The stock may trade near a narrow range. The cash consideration may feel well known. But the option market can still behave awkwardly because of wide spreads, thin residual time value, uncertain exercise incentives, and the possibility that market participants are pricing different assumptions about the post-close contract treatment.
That is why the last few hours in these names are less about taking a fresh fundamental view and more about execution quality, time decay, and understanding exactly what you own or are short.
What is confirmed, and what is still open
Confirmed facts
- Nasdaq says XOMA stockholders approved the merger on July 13, 2026.
- Nasdaq says July 13, 2026 is the anticipated last trading day for
XOMA,XOMAO, andXOMAP. - Nasdaq says the securities are expected to be halted after the after-hours session at around 7:50 p.m. ET on July 13.
- Nasdaq says the merger is tentatively scheduled to close before the market open on July 14, 2026 and that suspension would be effective July 15, 2026 if the closing occurs as planned.
- Nasdaq says XOMA common holders are to receive USD 39.00 in cash per share.
- Nasdaq says pre-merger XOMA common holders of record on July 13 will receive one non-transferable CVR per share, payable on July 14, and that the CVR distribution will not be quoted ex.
Interpretation
XOMAoptions are now best read as a final-session event instrument rather than a normal royalty-story equity option.- The CVR means the economic package is more nuanced than a textbook all-cash deal, even if the common stock still trades like a capped merger name.
- Residual extrinsic value and assignment discipline matter more than any fresh opinion on XOMA’s stand-alone fundamentals.
Still open
- Nasdaq’s stock-trading alert is not the final OCC contract-adjustment memo.
- The exact listed-options deliverable should not be treated as fully known until OCC publishes it.
- The stated closing timetable is still described as anticipated and tentative, which matters because timing revisions can change final-session assumptions.
What Traders May Misunderstand
“USD 39.00 cash means the options problem is solved”
Not necessarily. The common-stock package also includes a CVR, and listed-option treatment still depends on OCC’s formal adjustment terms. The price tag alone does not settle the contract mechanics.
“A non-transferable CVR is just like extra cash”
Wrong. A non-transferable litigation CVR is contingent by design. It may have economic value, but it does not behave like ordinary closing cash and should not be treated as certainty.
“Once the halt time is known, assignment risk disappears”
Wrong again. Assignment risk exists until the position is closed, expires, or is transformed by the official end-state contract terms. If extrinsic value gets thin enough, early exercise and assignment can still matter before the halt.
“Preferred redemptions tell me exactly what happens to common options”
No. They confirm the broader merger endgame is active, but the common-option contract terms still come from OCC, not from a preferred redemption notice.
“This is just a duplicate of the April merger announcement”
It is not. The announcement phase was about strategic value and takeover repricing. The July 13 phase is about last-trading-day timing, after-hours halt risk, CVR mechanics in the background, and the final-session behavior of listed options.
Bottom line
XOMA has moved from merger theory into merger plumbing. Nasdaq now says July 13, 2026 is the anticipated last trading day, the stock is expected to be halted after the after-hours session at around 7:50 p.m. ET, the merger is tentatively scheduled to close before the July 14 open, and common holders are slated to receive USD 39.00 in cash plus one non-transferable CVR per share.
For options traders, that combination matters because it turns the setup into a contract-handling problem. The useful focus is not on predicting where XOMA “should” trade next. It is on understanding the shrinking time window, the possibility of residual assignment risk, the difference between stockholder economics and listed-option deliverables, and the need to wait for the exact OCC end-state memo before treating the contract terms as settled.
This article is not financial, investment, or trading advice. Options involve substantial risk, including event timing risk, assignment risk, liquidity risk, and losses that can exceed what a trader initially expects.
Sources
- Nasdaq Trader Corporate Actions Alert #2026-430, July 13, 2026:
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-430 - XOMA press release, “Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator,” April 27, 2026:
https://investors.xoma.com/news-events/press-releases/detail/500/ligand-to-acquire-xoma-royalty-further-accelerating-profit - XOMA press release, “XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date,” June 12, 2026:
https://investors.xoma.com/news-events/press-releases/detail/501/xoma-royalty-corporation-declares-quarterly-preferred-stock - SEC Form 8-K filed by Ligand Pharmaceuticals Incorporated, April 27, 2026:
https://www.sec.gov/Archives/edgar/data/886163/000119312526179529/d143046d8k.htm - SEC Form 8-K filed by XOMA Royalty Corporation, June 12, 2026:
https://www.sec.gov/Archives/edgar/data/791908/000119312526269734/d143305d8k.htm
